BioNTech develops a broad product pipeline using different scientific approaches and cutting-edge technology platforms. BioNTech´s clinical pipeline represents a number of industry firsts.
A series of firsts:
BioNTech is the first company worldwide to
- Implement a medical genomics-driven design and GMP-approved manufacturing process for individual patient-specific therapies
- Advance an mRNA-based individualized cancer vaccine targeting neoantigens into clinical trials
- Enter the clinic with an mRNA-based individualized vaccine drawn from a warehouse of mRNAs encoding cancer-selective antigens
- Test an intravenous formulation of a mRNA vaccine in clinical trials